Abbott Labs Loves Merck More Than Gilead

Sometimes you have to make enemies to make new friends. Such is the case for Abbott Labs (NYSE: ABT  ) , which released data today testing its HIV drug, Kaletra, with Merck's (NYSE: MRK  ) Isentress compared with Kaletra plus Gilead Sciences' (Nasdaq: GILD  ) Truvada.

The data, which is only from the first half of a 96-week study, showed that the two combinations are equal in their ability to keep the HIV virus at bay in recently diagnosed patients. Considering that Isentress is a relatively new compound, having been approved less than three years ago, this is clearly a win for Merck. Grabbing some of the $2.5 billion in sales that Truvada managed last year sure would be nice; the allure of a potential revenue gain is the reason Merck supplied the Isentress to the study.

Running the study makes it look like Abbott loves Merck more than Gilead, but I think Abbott would be just as happy combining Kaletra with HIV drugs made by Johnson & Johnson (NYSE: JNJ  ) , GlaxoSmithKline (NYSE: GSK  ) , or Pfizer (NYSE: PFE  ) . There are multiple combination options for newly diagnosed HIV patients, and Abbott wants to make sure Kaletra is in the mix no matter what it pairs with. Truvada got the short straw because it was already known that the Kaletra-Truvada combination worked, and the trial had to compare the new combination to a currently prescribed treatment (it's not ethical to run clinical trials on HIV patients using placebo).

Abbott will consider making a single pill combining Kaletra and Isentress once the full study is complete. Combination products such as Gilead and Bristol-Myers Squibb's (NYSE: BMY  ) Atripla are preferred by doctors and their patients because they simplify the drug-taking process.

Gilead won't be all that excited about the news, but considering it's developing a four-drug quad pill of its own, I doubt there's any love lost between it and Abbott.

Tim Hanson and Brian Richards express their love for penny stocks.

Pfizer is a Motley Fool Inside Value recommendation. Johnson & Johnson is an Income Investor selection. Motley Fool Options has recommended buying calls on Johnson & Johnson. Try any of our Foolish newsletters today, free for 30 days

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool owns shares of GlaxoSmithKline. The Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 1238019, ~/Articles/ArticleHandler.aspx, 4/23/2014 9:05:25 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...